FIG. 06 / ANGION BIOMEDICA CORP.

A second listing. A second voice.

Angion's science had matured. Their brand had not. We expanded the visual and narrative system to match the company's clinical ambition, then carried it through the NASDAQ transition with IR-grade rigor.

Client: Angion Biomedica Corp.
Sector: Renal / Cardiovascular
Category: Biotech

FIG. 06.A / Image to be supplied

FIG. 06.A / Angion Biomedica Corp. brand application. Photography in production.

The Brief

Angion Biomedica Corp. is a clinical-stage biotech focused on renal and cardiovascular disease.

The pipeline had advanced. The brand and IR platform had not kept pace. They needed an expansion of the existing identity and a coordinated NASDAQ transition.

The Argument

The brand expansion preserved equity in the existing identity while elevating the system to read as a public-market participant.

IR platform transition coordinated with Notified ensured the regulatory layer felt like an extension of the brand, not a separate channel.

The Work

Brand expansion delivered as a system update, not a rebrand: the new work absorbed and elevated the existing equity.

IR platform transition coordinated end to end. NASDAQ integration completed with the existing brand voice intact.

325 is fast, economical, and really understands the needs of companies like ours. They made our integration with Notified painless from my perspective.